secwatch.observer — SEC 8-K summary
======================================

Issuer:     ArriVent BioPharma, Inc. (AVBP)
CIK:        0001868279
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001558370-24-015622
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ArriVent reports Q3 2024 cash of $282.9M, net loss $59.9M; firmonertinib clinical progress highlighted
--------------------------------------------------------------------------------

- Cash and cash equivalents $282.9M as of Sept 30, 2024; expected to fund operations into 2026.
- Net loss $59.9M for nine months ended Sept 30, 2024; R&D expenses $58.9M, G&A $11.8M.
- Positive interim firmonertinib data in EGFR PACC mutant NSCLC presented at WCLC 2024 with CNS activity.
- Phase 3 FURVENT trial top-line data for firmonertinib in EGFR exon 20 NSCLC expected in 2025.
- Dose expansion for firmonertinib plus SHP2 inhibitor expected in Q4 2024; ADC candidate selection by early 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1868279/000155837024015622/0001558370-24-015622-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1868279/000155837024015622/avbp-20241114x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-015622

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer